KPV Dosage: Immune Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

KPV · 10 mg Vial

KPV is dosed at 200 mcg–500 mcg daily via subcutaneous injection in educational protocols, often used in short anti-inflammatory cycles.

Typical daily range: 200–500 mcg once daily (gradual titration recommended).

Standard / Gradual Approach

Week	Daily Dose (mcg)
Week 1	200 mcg
Week 2	300 mcg
Week 3	400 mcg
Weeks 4–8	500 mcg

3 ml conversion

Select vial strength

10 mg + 3 ml = 3.33 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
200 mcg	6.0 units
300 mcg	9.0 units
400 mcg	12 units
500 mcg	15 units

Source chart on peptidedosages.com

Other immune compounds

LL-3737-amino-acid cathelicidin antimicrobial peptide ThymalinThymic peptide extract preparation Thymosin Alpha-128-amino-acid thymic peptide VilonSynthetic immunoregulatory dipeptide VIP28-amino-acid neuropeptide AdamaxCyclic Semax analogue (cyclo-prolylglycine related)

All research protocols

KPV: research background

What the compound is

KPV (lysine-proline-valine) is a tripeptide derived from the C-terminal (end) portion of alpha-melanocyte-stimulating hormone (α-MSH) (PMID 12750433, PMID 30661264). It is a truncated form of α-MSH and a peptide analogue (PMID 30661264, PMID 41880199). Unlike α-MSH, KPV lacks the pigment-inducing activity (PMID 30661264).

How it is thought to work

KPV is believed to exert anti-inflammatory effects that are distinct from those of core MSH peptides. Evidence suggests it is unlikely to act through melanocortin receptors but may inhibit interleukin-1 beta (IL-1β) functions (PMID 12750433). In immortalized human bronchial epithelial cells, KPV suppressed NFκB signaling by inhibiting the nuclear import of p65RelA, a key protein in inflammatory pathways, and stabilizing another protein called IκBα (PMID 22837805). KPV has also been associated with inhibiting inflammatory responses and activating autophagy, a cellular self-cleaning process, in mice with vascular calcification (PMID 39252648). In vitiligo, KPV-modified liposomes carrying gene-silencing RNA (shRNA) were found to alleviate disease progression by targeting the NLRP3 inflammasome, suggesting a role in reducing inflammation and pyroptosis (a type of programmed cell death) in melanocytes (PMID 40935835).

What laboratory and animal studies report

In mice, systemic treatment with KPV significantly reduced the accumulation of polymorphonuclear leukocytes in the peritoneal cavity in a model of crystal-induced peritonitis and also reduced inflammation in IL-1β-induced peritonitis (PMID 12750433). KPV's anti-inflammatory properties were observed even in mice with a nonfunctional MC1-R receptor (PMID 12750433). In rats with TNBS-induced ulcerative colitis, intracolonic administration of KPV, especially when delivered via a hydrogel, significantly improved the alleviating effect and restored the epithelial barrier. It also modulated gut flora, increasing beneficial microorganisms (PMID 35245681). In vitro, macrophage activation (release of KC and IL-1β) was not inhibited by KPV (PMID 12750433). In immortalized human bronchial epithelial cells, KPV dose-dependently inhibited NFκB, matrix metalloproteinase-9 activity, and the secretion of inflammatory signals like IL-8 and eotaxin (PMID 22837805). KPV and rapamycin (RAPA) self-assembled into nanoparticles inhibited vascular calcification in mice by reducing inflammation and activating autophagy (PMID 39252648). A KPV-based conjugate (proKPV) delivered orally in mice with colitis showed a 3.8-fold greater accumulation in the colon and enhanced efficacy, even at a lower dose, compared to free KPV. Oral proKPV also accumulated in inflamed lungs and showed anti-inflammatory effects in mice with acute lung injury (PMID 41533788).

Open questions and limitations

While promising in laboratory and animal models, the clinical evidence supporting peptide use like KPV in sport and the general population is limited (PMID 41880199). Most published studies examine therapeutic applications under controlled dosing, which differs from protocols sometimes used in bodybuilding (PMID 41880199). Long-term risks and prevalence of KPV use in humans are largely unknown, and products in unregulated supply chains can be mislabeled or contaminated (PMID 41880199).

Key terms explained

**Polymorphonuclear leukocyte:** A type of white blood cell involved in inflammation (PMID 12750433). **Melanocortin receptors (MC1R, MC3/4-R):** Receptors on cells that bind melanocortin peptides and are involved in various physiological processes, including inflammation and pigmentation (PMID 12750433, PMID 30661264). **Interleukin-1 beta (IL-1β):** A cytokine, a signaling protein that plays a key role in inflammation (PMID 12750433). **NFκB (Nuclear Factor kappa-light-chain-enhancer of activated B cells):** A protein complex that controls DNA transcription, cytokine production, and cell survival, and is a key regulator of inflammatory responses (PMID 22837805). **Autophagy:** A cellular process where cells 'eat' their own damaged parts or invaders, essential for cell health and involved in various diseases (PMID 39252648). **Vascular calcification (VC):** The buildup of calcium in blood vessels, a risk factor for cardiovascular disease (PMID 39252648). **NLRP3 inflammasome:** A protein complex inside cells that senses danger signals and triggers an inflammatory response (PMID 40935835).

Studies cited in this section

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. — The Journal of pharmacology and experimental therapeutics, 2003 (PMID 12750433)
Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. — Science advances, 2026 (PMID 41533788)
KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. — Advanced healthcare materials, 2024 (PMID 39252648)
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness, 2026 (PMID 41880199)
Are melanocortin peptides future therapeutics for cutaneous wound healing? — Experimental dermatology, 2019 (PMID 30661264)
A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. — Acta biomaterialia, 2022 (PMID 35245681)
Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. — International journal of physiology, pathophysiology and pharmacology, 2012 (PMID 22837805)
NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development. — Cell death and differentiation, 2026 (PMID 40935835)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

KPV dosage protocol